Wenshen Xiaozheng Tang suppresses the growth of endometriosis with an antiangiogenic effect

Climacteric

Volumn 16, Issue 6, 2013, Pages 700-708

  Zhang, Z Z ^a,b   Hu, C P ^b   Tang, W W ^a,b   Gui, T ^a,b   Qian, R Y ^a,b   Xing, Y X ^a,b   Cao, P ^b   Wan, G P ^a,b  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b Jiangsu Province Academy of Traditional Chinese Medicine   (China)

Author keywords

Angiogenesis; Endometriosis; VEGF; Wenshen Xiaozheng Tang

Indexed keywords

ANGIOGENESIS INHIBITOR; CHINESE DRUG; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; WENSHEN XIAOZHNG TANG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MEGADOSE; ENDOMETRIOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; NONHUMAN; PERITONEAL FLUID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; ASCITIC FLUID; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; ENDOMETRIOSIS; FEMALE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOVASCULARIZATION, PATHOLOGIC; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84887903146     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2013.771331     Document Type: Article

References (36)

1. Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005;20:2698-704
2. Bricou A, Batt R E, Chapron C. P eritoneal fl uid fLow infl uences anatomical distribution of endometriotic lesions: Why Sampson seems to be right. Eur J Obstet Gynecol Reprod Biol 2008;138:127-34
3. D'Hooghe T M, Debrock S. E ndometriosis, retrograde menstruation and peritoneal infl ammation in women and in baboons. Hum Reprod Update 2002;8:84-8
4. Ozkan S, Arici A. A dvances in treatment options of endometriosis. Gynecol Obstet Invest 2009;67:81-91
5. Rocha AL, Reis FM, Petraglia F. New trends for the medical treatment of endometriosis. Expert Opin Investig Drugs 2012;21:905-19
6. Taylor HS, Osteen KG, Bruner-Tran KL, et al. Novel therapies targeting endometriosis. Reprod Sci 2011;18:814-23
7. Hoeben A, Landuyt B, Highley M S, Wildiers H, Van Oosterom A T, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56:549-80
8. Fasciani A, D 'Ambrogio G, Bocci G, Monti M, Genazzani A R, Artini PG. High concentrations of the vascular endothelial growth factor and interleukin-8 in ovarian endometriomata. Mol Hum Reprod 2000;6:50-4
9. Pupo-Nogueira A, d e Oliveira R M, Petta C A, Podgaec S, Dias JA Jr, Abrao MS. Vascular endothelial growth factor concentrations in the serum and peritoneal fl uid of women with endometriosis. Int J Gynaecol Obstet 2007;99:33-7
10. McLaren J, Prentice A, Charnock-Jones D S, Smith S K. V ascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fl uid of women with endometriosis. Hum Reprod 1996;11:220-3
11. Cho S, Choi YS, Jeon YE, et al. Expression of vascular endothelial growth factor (VEGF) and its soluble receptor-1 in endometriosis. Microvasc Res 2012;83:237-22
12. Mahnke J L, Dawood M Y, Huang J C. V ascular endothelial growth factor and interleukin-6 in peritoneal fl uid of women with endometriosis. Fertil Steril 2000;73:166-70
13. Shifren J L, Tseng J F, Zaloudek C J, e t a l. O varian steroid regulation of vascular endothelial growth factor in the human endometrium: Implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. J Clin Endocrinol Metab 1996;81:3112-18
14. Becker CM, Rohwer N, Funakoshi T, et al. 2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis. Am J Pathol 2008;172:534-44
15. Semenza GL, Shimoda LA, Prabhakar NR. Regulation of gene expression by HIF-1. Novartis Found Symp 2006;272:2-8
16. Greijer A E, van der Groep P, Kemming D, et al. U p-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 2005;206:291-304
17. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007;19:2003-12
18. Sato Y, Kanno S, Oda N, et a l. P roperties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann NY Acad Sci 2000;902:201-5
19. Wieser F, Cohen M, Gaeddert A, et al. Evolution of medical treatment for endometriosis: Back to the roots? Hum Reprod Update 2007;13:487-99
20. Flower A, Liu JP, Chen S, Lewith G, Little P. Chinese herbal medicine for endometriosis. Cochrane Database Syst Re v 2009;3:CD006568
21. Wang L, Zhou GB, Liu P, e t al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 2008;105:4826-31
22. Wang X, Zhang A, Sun H. F uture perspectives of chinese medical formulae: Chinmedomics as an effector. Omics 2012;16:414-21
23. Yavuz E, Oktem M, Esinler I, Toru SA, Zeyneloglu HB. Genistein causes regression of endometriotic implants in the rat model. Fertil Steril 2007;88:1129-34
24. Szymanowski K, Chmaj-Wierzchowska K, Yantczenko A, et al. Endometriosis prophylaxis and treatment with the newly developed xenogenic immunomodulator RESAN in an animal model. Eur J Obstet Gynecol Reprod Biol 2009;142:145-8
25. Ji X, Gao J, Cai X, e t al. Immunological regulation of Chinese herb Guizhi Fuling Capsule on rat endometriosis model. J Ethnopharmacol 2011;134:624-9
26. Olivares C, Ricci A, Bilotas M, Baranao R I, Meresman G. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil Steril 2011;96:428-33
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8
28. Zhu Y P, Woerdenbag H J. T raditional Chinese herbal medicine. Pharm World Sci 1995;17:103-12
29. Tindle H A, Davis R B, Phillips R S, Eisenberg D M. T rends in use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 2005;11:42-9
30. Burks-Wicks C, Cohen M, Fallbacher J, RNT, Wieser F. A Western primer of Chinese herbal therapy in endometriosis and infertility. Womens Health 2005;1:447-63
31. Taylor RN, Mueller MD. Anti-Angiogenic treatment of endometriosis: Biochemical aspects. Gynecol Obstet Invest 2004;57:54-6
32. Al-Salam S, Balalaa N, Faour I, Akhter S, Alashari M. HIF-1alpha, VEGF and WT-1 are protagonists in bilateral primary angiosarcoma of breast: A case report and review of literature. Int J Clin Exp Pathol 2012;5:247-53
33. Chen P, Yin H, Wang Y, Wang Y, Xie L. Inhibition of VEGF expression and corneal neovascularization by shRNA targeting HIF-1alpha in a mouse model of closed eye contact lens wear. Mol Vis 2012;18:864-73
34. Olsson A K, Dimberg A, Kreuger J, Claesson-Welsh L. V EGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006;7:359-71
35. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001;49:568-81
36. Griffi oen A W, Molema G. A ngiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic infl ammation. Pharmacol Rev 2000;52:237-68